Higher efficacy of rupatadine 20 mg and 10 mg versus placebo in patients with perennial allergic rhinitis: a pooled responder analysis
Abstract Background The clinical efficacy of rupatadine in terms of responders has not been previously explored in perennial allergic rhinitis (PAR). Methods This pooled analysis included data from 6 randomised, double-blind, placebo-controlled trials conducted in PAR patients treated with rupatadin...
Main Authors: | Antonio Valero, Iñaki Izquierdo, Marek L. Kowalski, Glenis K. Scadding, Jean Bousquet, Joaquim Mullol |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-04-01
|
Series: | Allergy, Asthma & Clinical Immunology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13223-020-00425-1 |
Similar Items
-
Clinically relevant effect of rupatadine 20 mg and 10 mg in seasonal allergic rhinitis: a pooled responder analysis
by: Joaquim Mullol, et al.
Published: (2019-10-01) -
Rupatadine oral solution for 2–5-year-old children with allergic rhinitis: a safety, open-label, prospective study
by: Santamaría E, et al.
Published: (2018-09-01) -
Platelet-Activating Factor (PAF) in Allergic Rhinitis: Clinical and Therapeutic Implications
by: Rosa M. Muñoz-Cano, et al.
Published: (2019-08-01) -
Comparison of Loratadine and Cetirizine in Perennial Allergic Rhinitis
by: Ali Eftekharian, et al.
Published: (2015-07-01) -
Allergic rhinitis
by: S. V. Ryazantsev, et al.
Published: (2018-11-01)